M. tuberculosis antigens
AssigneeStatens Serum Institut
InventorsPeter Andersen, Rikke Louise Vinther Skjot
Life of this patent
Estimating the term…
Abstract
The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides.
Claims29
A substantially pure polypeptide, which comprises an amino acid sequence selected from
- (a) the group consisting of Rv0288 (SEQ ID NO:
- 2) and its homologues Rv3019c (SEQ ID NO:
- 199) and Rv3017c (SEQ ID NO:
- 197);
- (b) an immunogenic portion, e.g. a T-cell epitope, of any one of the sequences in (a);
- and/or
- (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic.
A fusion polypeptide which comprises an amino acid sequence selected from
- (a) the group consisting of Rv0288 (SEQ ID NO:
- 2) and its homologues Rv3019c (SEQ ID NO:
- 199) and Rv3017c (SEQ ID NO:
- 197);
- (b) an immunogenic portion, e.g. a T-cell epitope, of any one of the sequences in (a);
- and /or
- (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic;
- and at least one fusion partner.
A polypeptide which comprises an amino acid sequence selected from
- (a) the group consisting of Rv0288 (SEQ ID NO:
- 2) and its homologues Rv3019c (SEQ ID NO:
- 199) and Rv3017c (SEQ ID NO:
- 197);
- (b) an immunogenic portion, e.g. a T-cell epitope, of any one of the sequences in (a);
- and/or
- (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic;
- which is lipidated so as to allow a self-adjuvating effect of the polypeptide.
Use of a polypeptide according to any of the preceding claims for the preparation of a pharmaceutical composition for diagnosis, e.g. for diagnosis of tuberculosis caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis.
Use of a polypeptide according to any of the preceding claims for the preparation of a pharmaceutical composition, e.g. for the vaccination against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis.
An immunogenic composition comprising a polypeptide according to any of the preceding claims.
A pharmaceutical composition which comprises an immunologically responsive amount of at least one member selected from the group consisting of:
- (a) a polypeptide selected from the group consisting of Rv0288 (SEQ ID NO:
- 2), Rv3019c (SEQ ID NO:
- 199), Rv3017c (SEQ ID NO:
- 197) and an immunogenic portion of any of these polypeptides;
- (b) an amino acid sequence which has a sequence identity of at least 70% to any one of said polypeptides in (a) and is immunogenic;
- (c) a fusion polypeptide comprising at least one polypeptide or amino acid sequence according to (a) or (b) and at least one fusion partner;
- (d) a nucleic acid sequence which encodes a polypeptide or amino acid sequence according to (a), (b) or (c);
- (e) a nucleic acid sequence which is complementary to a sequence according to (d);
- (f) a nucleic acid sequence which has a length of at least 10 nucleotides and which hybridizes under stringent conditions with a nucleic acid sequence according to (d) or (e);
- and
- (g) a non-pathogenic micro-organism which has incorporated (e.g. placed on a plasmid or in the genome) therein a nucleic acid sequence according to (d), (e) or (f) in a manner to permit expression of a polypeptide encoded thereby.
A method for stimulating an immunogenic response in an animal which comprises administering to said animal an immunologically stimulating amount of at least one member selected from the group consisting of:
- (a) a polypeptide selected from the group consisting of Rv0288 (SEQ ID NO:
- 2), Rv3019c (SEQ ID NO:
- 199), Rv3017c (SEQ ID NO:
- 197) and an immunogenic portion of any of these polypeptides;
- (b) an amino acid sequence which has a sequence identity of at least 70% to any one of said polypeptides in (a) and is immunogenic;
- (c) a fusion polypeptide comprising at least one polypeptide or amino acid sequence according to (a) or (b) and at least one fusion partner;
- (d) a nucleic acid sequence which encodes a polypeptide or amino acid sequence according to (a), (b) or (c);
- (e) a nucleic acid sequence which is complementary to a sequence according to (d);
- (f) a nucleic acid sequence which has a length of at least 10 nucleotides and which hybridizes under stringent conditions with a nucleic acid sequence according to (d) or (e);
- and
- (g) a non-pathogenic micro-organism which has incorporated therein (e.g. placed on a plasmid or in the genome) a nucleic acid sequence according to (d), (e) or (f) in a manner to permit expression of a polypeptide encoded thereby.
Dependencies are inferred from the claim text.